European Journal of Molecular & Clinical Medicine

Abstract

Background: Prostate cancer is the second most common cancer in men and the fourth most common cancer overall. 1.4 million new cases of prostate cancer diagnosed in 2020. PSA and Gleason's score (GS) before treatment are important diagnostic and therapeutic indicators. According to studies, GS degrades tumors while PSA is not cancer-specific. The current study studies the relationship between Ki67, GS, and PSA, which is used to grade tumors and predict patient prognosis. Objectives: 1. To study the histopathology of prostate carcinoma and its variants and assign them a Gleason score as per the Gleason grading system. 2.To study Ki-67 immuno expressing in prostate carcinoma. 3. To correlate Ki-67 expression, Gleason scoring, and serum prostate-specific antigen levels in prostate carcinoma, Methods: A retrospective study enrolled 80 prostate cancer patients from Malla reddy Medical College, Hyderabad from November 2019 to April 2021.Each instance received a Gleason score and Ki67 immunohistochemistry. Ki67 expression and Gleason score were found to be related. Results: All 80 patients were diagnosed with acinar/normal adenocarcinoma-WHO. There were 36 patients with moderately-differentiated tumors (45%) , 28 with high grades (35 percent), and 16 with intermediate grades. PSA levels rose as a result of GS. GS and serum PSA levels increased in direct proportion to Ki6l abeling. Conclusion: Ki67 is a novel biomarker linked to tumor grade and pretreatment PSA levels. It can be used as a diagnostic parameter or to replace prognostic factors.